Wrap Text
Cryo-Vacc Launches in South Africa with Working Prototype
RENERGEN LIMITED
Incorporated in the Republic of South Africa
(Registration number: 2014/195093/06)
JSE Share code: REN
A2X Share code: REN
ISIN: ZAE000202610
LEI: 378900B1512179F35A69
Australian Business Number (ABN): 93 998 352 675
ASX Share code: RLT
(“Renergen” or “the Company”)
CRYO-VACC LAUNCHES IN SOUTH AFRICA WITH WORKING PROTOTYPE
Helium and natural gas company Renergen is proud to announce the completion and successful
operation of the Company’s first Cryo-VaccTM prototype, which is being presented to South African
based media at its headquarters in Johannesburg, today at 10am SAST.
Cryo-VaccTM was designed and patented by Renergen for efficient transport and storage of ultra-
cold biologics for periods of up to 25 days or longer in transit, where access to an external power
source is not possible. The Cryo-VaccTM has a temperature range of -150 ºC to 8ºC, making it
highly versatile for a range of vaccines.
Combined with best-in-class cold chain monitoring and asset tracking technology from Beyond
Wireless Proprietary Limited (“Beyond”), a World Health Organisation Performance, Quality and
Safety (PQS) certified remote temperature monitoring solution provider, the Cryo-VaccTM can
provide accurate temperature readings of the vaccines whilst in transit, as well as GPS tracking
to ensure the custody chain can be audited.
Beyond is an Internet of Things (IoT) solutions provider, specialising in remote temperature
monitoring and control, with a specific focus on the global public healthcare sector. Beyond has
active deployments in over 70 countries and are proud to partner with numerous for-profit
enterprises, Ministries of Health, as well as several non-governmental organisations including
UNICEF, the World Health Organisation, the International Committee for the Red Cross, and the
Pan American Health Organisation.
“Our mission is to improve human health, quality of life, and secure humanity's future by
leveraging the power and reach of the Internet of Things (IoT). We believe that eradicating
poverty, hunger and inequality starts with preventing disease. It's simple - healthy communities
are happier, safer and more prosperous. We are proud to partner with Renergen on Cryo-VaccTM”
said Ian Lester, founder and CEO, Beyond.
Cryo-VaccTM is ideal for both air and ground transportation, utilising liquid nitrogen to transport by
road and helium to transport by air. Aside from helium being only a fraction of the weight of
nitrogen, significantly reducing its cost in airfreight, when used in Cryo-VaccTM helium can
accommodate up to 12 times more vials per flight compared to other cryogens based on current
flight safety regulations.
With the recent release of the NDoH tender for the distribution of vaccines in South Africa,
Renergen has teamed up with local express courier partner, DPD Laser, which is part of The
Laser Group and known for its last mile courier express capabilities and infrastructure throughout
South Africa.
“DPD Laser has been proudly serving South Africa for over 30 years, and we are excited to bring
our extensive coverage and best-in-breed, technology-driven delivery services to enable mission-
critical vaccine distribution using Cryo-VaccTM” said Anton Visagie, CEO, DPD Laser.
Validation of the Cryo-VaccTM in anticipated deployment situations will commence shortly, but
Renergen has already commenced discussions for the sale of units to logistics companies outside
of the South African Development Community (SADC).
“Precise temperature control combined with a formidable hold time in transit, makes Cryo-VaccTM
a compelling asset in the transport of biologics, especially in the developing world. With a useful
temperature range of over 150 ºC, Cryo-VaccTM is very versatile when compared to even standard
refrigeration technology. Every Renergen team member is truly proud to be associated with such
an innovative product and we hope that Cryo-VaccTM helps save many lives and restore some
normality as the world builds herd immunity,” said Renergen CEO Stefano Marani.
Johannesburg
15 February 2021
Authorised by: Stefano Marani
Chief Executive Officer
Designated Advisor
PSG Capital
For South African investor inquiries, contact Renergen
info@renergen.co.za
+2710 045 6007
For South African media queries contact OwnAlchemy
Michael Rubenstein
+2782 903 7797
michael@ownalchemy.com
For Australian Investors & Media, contact Citadel-MAGNUS
Cameron Gilenko
0466 984 953
www.renergen.co.za
Date: 15-02-2021 10:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
